EP4228678A1

EP4228678A1 - Parapharmaceutical or pharmaceutical composition administrable to a living being, preferably a human being, comprising at least one enzyme for the treatment and/or prevention of bacterial infections involving biofilm formation

Info

Publication number: EP4228678A1
Application number: EP21797993.9A
Authority: EP
Inventors: Laetitia Fontaine; Aline LARDINOIS; Houssein CHALHOUB; Françoise VAN BAMBEKE; Albert RUIZ-SORRIBAS
Original assignee: Onelife SA; Universite Catholique de Louvain UCL
Current assignee: Onelife SA; Universite Catholique de Louvain UCL
Priority date: 2020-10-16
Filing date: 2021-10-18
Publication date: 2023-08-23
Also published as: WO2022079315A1; BE1028712B1; BE1028712A1; US20230390366A1

Abstract

A parapharmaceutical or pharmaceutical composition administrable to living beings, in particular to human beings, comprising at least one endoribonuclease enzyme chosen from the EC 3.1.30 and EC 3.1.31 classes, preferably in a content of from 10 to 1000 U/ml, preferably 50 to 500 U/ml, preferably from 100 to 500 U/ml, for use in a curative or preventive treatment for dermatological infections or for infections which develop on superficial or deep burns and wounds.

Description

PARA-PHARMACEUTICAL OR PHARMACEUTICAL COMPOSITION ADMINISTRABLE TO A LIVING BEING, PREFERABLY A HUMAN BEING COMPRISING AT LEAST ONE ENZYME FOR THE TREATMENT AND/OR PREVENTION OF BACTERIAL INFECTIONS INVOLVING THE FORMATION OF BIOFILM

The present invention relates to a parapharmaceutical or pharmaceutical composition which can be administered to living beings and in particular to humans, comprising at least one enzyme and to its use as a potentiator in the treatment and/or prevention of bacterial infections involving the formation of biofilm, such as post-implantation infections, linked to medical implants in situ, and therefore implanted, and various infections of the body such as acute or chronic infections of wounds, burns, infections of the oral cavity, digestive tract, urinary system, respiratory system.

A biofilm is a viscous film which develops on all surfaces, following the adhesion of microorganisms to these surfaces and the secretion by them of polymers which cover them and facilitate their adhesion. Biofilms thus constitute a protective layer around microorganisms and represent a recurrent source of contamination of the surrounding environment which poses major problems in terms of health, for example in hospital environments.

More specifically, the accumulation of polymers secreted by bacteria creates a matrix composed essentially of polysaccharides, DNA, proteins as well as lipids which protects these microorganisms from external aggressions and which has a very strong resistance to cleaning and cleaning procedures. conventional disinfection. Microorganisms therefore easily develop within this protective matrix and contaminate the surrounding environment by constituting a particularly critical reservoir that is difficult to eliminate.

It is recognized that the problem of the presence of biofilms is twofold. First, as indicated above, these represent a source of permanent contamination and very difficult to eliminate by conventional means, even the most aggressive. Indeed, conventional disinfectants are very often ineffective because it is observed that they fail to reach the microorganisms that are protected by the biofilm matrix composed of polysaccharides, DNA, proteins and lipids.

Second, a biofilm is mixed, in the sense that it is initially developed by certain bacterial strains but can harbor others, these strains living and growing in colonies. However, these colonies promote communication between bacteria and, among other things, the exchange and propagation of resistance genes carried by certain bacteria. The biofilms resulting from these exchanges of genes are then even more difficult to eliminate and it is necessary to resort to increasingly powerful means of disinfection or treatment which, however, frequently come up against major problems of resistance and/or tolerance.

The protective matrix of the bacteria forming the biofilms is so resistant that it constitutes a real barrier protecting the bacteria from the microbicidal agents (antibiotics and/or biocides) which could act against the microorganisms and therefore against the infections linked to the presence of biofilms, including infections of the human body associated with the presence of biofilm. Currently, conventional treatments based on different antibiotics and/or different biocides (disinfectants, etc.), even when they are, in certain cases, in combination with other compounds (formulated detergents and/or sequestrants and/or or dispersants and/or surfactants), do not act sufficiently effectively because they do not penetrate or only to a limited extent the biofilm in its thickness. Furthermore, microbicides can be inhibited by certain molecules making up this matrix. Consequently, the current treatments are only partially effective, and act only on the surface of the biofilm, the matrix of the biofilm effectively protecting the bacteria from phenomena of dehydration, from the action of antibiotics and biocides (and more generally from microbicidal molecules ), phagocytosis and acids. In this sense, it is also generally accepted that biofilms have a resistance up to 1000 times greater to microbicides compared to a planktonic bacterium (not protected by a biofilm).

It is therefore understood that the treatment and/or prevention of bacterial infections involving the formation of biofilms is a real challenge because the bacteria are protected from microbicidal agents and external attacks.

In a hospital, dental or veterinary environment, the situation is all the more critical as many microorganisms responsible for the formation of biofilms are detected in many places, both at the level of individual patients/animals (wounds, wounds, burns, respiratory system, etc.) and at the level of the environment (operating room, cabinet and dental equipment, surgical equipment, maintenance equipment for this equipment, endoscopes, urinary catheters, catheters, dental implants or prostheses, medical equipment, dialysis or assisted ventilation apparatus for individuals, etc.) and surfaces (floors, walls, tables operation, ...).

At the same time, the treatment of wounds, a rapidly evolving field, is also largely concerned with bacterial infections involving the formation of biofilms. Present in more than 90% of chronic wounds, biofilm is a major obstacle to healing, increasing the inflammatory response and delaying the healing process.

Acute or chronic wounds/injuries include surgical wounds, burns, venous and arterial leg ulcers, diabetic foot ulcers, pressure ulcers (bedsores), burns... Chronic ulcers are extremely painful and difficult to treat. A wound is said to be chronic when no sign of healing is apparent after 4 to 6 weeks.

Wound treatment consists of two segments: the traditional wound treatment segment and the advanced active wound treatment segment. Traditional wound care is all about dressing in a dry environment to cover wounds and protect them from the environment.

Advanced active treatment of wounds/injuries concerns all treatments that provide real support for the healing and healing of wounds, sometimes including the debridement of damaged tissue. This treatment will stimulate the growth of new tissues and help control infection and pain.

The field of personal hygiene or cosmetic care is also affected by bacterial infections linked to the formation of biofilms. Mention was made above of dentistry practices for post-implantation infections following the fitting of dental prostheses (peri-implantitis). However, there are other applications where biofilms have a negative impact on health. For example, we know that teeth, gums, and dentures are carriers of choice for bacteria given the moist oral environment rich in microorganisms in which they are located. It is reported that the biofilm that makes up dental plaque is a major risk factor for complications such as cavities, periodontal disease and gingivitis and it is recognized that when the biofilm becomes thick, it represents resistance to chemicals (antibiotics, disinfectants) . In addition, respiratory disease is often linked to periodontal disease by transfer of microorganisms from the mouth to the respiratory tract. However, it is possible to reduce the health risks associated with dental plaque by preventing and/or reducing its formation through mechanical action.

On this subject, Kaplan et al. describe a mutated dispersin B which is a |3-N-acetylglucosaminidase (of EC class 3.2.1.52) in oral hygiene products such as toothpaste or mouthwash. Another example is in the treatment of onychomycosis (nail infection) or ocular lenses where biofilms are also involved or even acne. For example, WO 2020/0185685 describes a composition for the treatment of acne, which may contain "an RNA inhibitor".

From all this, it emerges that biofilms constitute a real challenge, particularly in the field of care, in particular health care (hospitals, dental surgeries, etc.) and veterinary care or even hygiene care.

This problem is all the more critical since biofilms involve bacteria responsible for potentially fatal infections in individuals, for example in individuals developing an infection caused by bacteria of the genus Staphylococci or Enterobacteriaceae which prove to be multi-resistant. next-generation antibiotics. It is therefore necessary to take all possible precautions to avoid the formation and development of biofilms.

Compositions comprising at least one enzyme for dispersing a biofilm are well known in the state of the art. For example, documents US2009/0130082 and WO2009/121183 relate to compositions comprising a bovine DNase I (endodeoxyribonuclease I of class EC 3.1.21) to disperse the biofilm and an antibiotic (microbicidal agent) to kill the bacteria released. According to these prior documents, these compositions are in particular used during the manufacture/preparation of medical devices for treating wounds. To this end, the medical devices are coated (coated) or impregnated with a composition comprising a DNase I and an antibiotic. More specifically, these prior documents essentially teach that such compositions are used to prepare medical devices and to disinfect the skin or the surrounding environment before insertion or implantation of a medical device. In this sense, the compositions disclosed in these prior documents are essentially used as coatings or as pre-procedure rinsing solutions before surgery, for example.

US 10,328,129 describes the use of nucleases for the treatment of eye conditions.

WO 01/93875 describes a composition for the treatment of a biofilm comprising a first enzymatic component provided with an anchor for the degradation of the structures of the biofilms and a second enzymatic component provided with an anchor having a direct bactericidal effect. The DNAses are indicated as belonging to this second enzymatic category.

US 2017/355930 describes a detergent product comprising a nuclease and an amine.

With this in mind, application EP 3468583 is known, which describes a composition comprising at least one enzyme such as for example a DNase I and at least one microbicidal molecule for the prevention or treatment of post-implantation biofilm infections.

Furthermore, the issue of biofilm infections is not limited to post-implantation biofilm infections. Indeed, biofilms are also involved in chronic infections of the animal body. As explained above, these infections can be present, for example, at the level of wounds/wounds present on the surface of the human body or the body of mammals.

We can also refer to patent application WO2006/133523 which describes a composition comprising at least one enzyme used in the treatment of dermatological problems and wounds. This composition includes at least a peroxidase for the purpose of generating antimicrobial hypothiocyanite radicals from H2O2 and thiocyanate for the treatment of infections.

Unfortunately, as can be seen, the state of the art is rich in lessons given the diversity of infections, such as for example those in which biofilms are involved. In some cases, the authors of research work have sought to identify an enzyme that will have a specific and/or targeted action against biofilms, while others have focused on an antimicrobial action without taking the matrix into account. biofilm.

Alternatively, we can know commercial solutions such as EnziQure® which is a multi-enzymatic detergent allowing the curative dissolution of the biofilm and the deep cleaning of surgical instruments and endoscopes. EnziQure® is a formulated product that contains a non-ionic surfactant base, dispersing and sequestering agents and an enzymatic cocktail containing 7 enzymes to be able to degrade the biofilm matrix of many bacterial species (its anti-biofilm action has been demonstrated on more than 15 strains), the enzymes being present in high concentrations to ensure maximum effectiveness.

Although very effective for cleaning medical instruments, this solution is a Class I medical device which cannot be administered to living beings, in particular to humans due to its detergent and enzymatic composition which has no not have the pharmaceutical grade required for its use as an active substance (medicine).

There is therefore currently a need to develop alternative formulations which can be applied to the body of a living being, in particular to the human or animal body, in particular for the treatment and/or prevention of bacterial infections involving the formation of biofilm and exhibiting an efficacy similar to that of the EnziQureO product of the applicant of the present patent application.

The object of the present invention is therefore to provide an enzymatic composition which can be administered to humans both externally and internally and whose effectiveness is similar to that of the detergent product EnziQure® vis-à-vis the dissolution of the matrix of biofilms and having a versatility of use.

By the terms “versatile use” or “versatility of use”, is meant a use on a wide panel of strains of bacteria and for a diversity of application, namely a use which has a wide spectrum of actions.

Indeed, for it to be possible to industrially exploit a formulation for the treatment and/or prevention of bacterial infections involving the formation of biofilm, it is advantageous to have a formulation with a broad spectrum of action, c ie capable of dissociating different types of biofilm associated with different types of infection. Indeed, the composition of a biofilm varies according to the bacteria that compose it, and therefore to the location and type of infection. Such a formulation would therefore be suitable for various applications, and would avoid the need to create different formulations depending on the type of infection targeted, since this approach involves a logistical complexity that penalizes industrial exploitation of such a formulation. The possibility of obtaining a formulation which is active in the treatment and/or prevention of bacterial infections involving the formation of biofilms from a wide range of bacterial strains and intended for different applications allows at least the manufacture of a concentrate which can then be diversified for certain applications or to formulate a versatile composition.

To solve this problem, provision is made according to the invention for the use of a para-pharmaceutical or pharmaceutical composition which can be administered to living beings, in particular to human beings, comprising at least one endoribonuclease enzyme chosen from the group consisting of enzymes belonging to classes EC 3.1.30 (for example EC.3.1.30.1 or EC.3.1.30.2) and EC 3.1.31 and their mixture, to potentiate a microbicidal agent, in particular an antibiotic, a phage, an antifungal, or a disinfectant, in the treatment and/or prevention of bacterial infections involving the formation of biofilm.

By way of example, such an enzyme is denarase® or benzonase endonuclease®. They are preferably present at a rate of 10 to 1000U/ml, preferably 50 to 500U/ml, preferably 100 to 500U/ml. Concentrations according to the present invention of said at least one endoribonuclease enzyme chosen from the group consisting of enzymes belonging to classes EC 3.1 .30 (EC.3.1 .30.1 or EC.3.1 .30.2) and EC 3.1 .31 is for example 200 U/ml to 650 U/ml, more particularly from 250 U/ml to 550 U/ml, preferably from 300 U/ml, or even from 350 U/ml to 500 U/ml. When several endoribonucleases are used together, either each present at the aforesaid concentration, or together, they present the aforesaid concentration.

The concentration is expressed according to the present invention in terms of U/ml. One unit (U) is equal to the amount of protein which induces a change in absorbance at 260nm of 1.0 in 30 minutes at 37°C.

As can be seen, the composition used according to the present invention is a para-pharmaceutical or pharmaceutical composition, which can be administered to living beings, in particular to human beings. When the composition is pharmaceutical, it is essentially free of endotoxin.

By the terms "substantially endotoxin-free composition" is meant a composition which contains no or very little toxic thermostable lipopolysaccharide substance. Typically depending on the organism from which the enzyme originates, the enzyme solution often contains endotoxins, which are present in the outer membrane of Gram-negative bacteria. Endotoxins are released during the extraction of the enzyme from the cell during cell lysis. Such enzymes are widely marketed, but are by no means suitable for pharmaceutical use, especially since they are generally not produced according to Good manufacturing Practice standards. It is possible to obtain an endotoxin-free enzyme either by production in gram+ bacteria, or in other hosts not containing endotoxins in their membrane, or even by purification.

Said at least one endoribonuclease enzyme of the composition used according to the present invention has an activity on RNA and on DNA. Its enzymatic activity hydrolyzes DNA and RNA substrates into 5'-phospho(mono/oligo)nucleotide products (EC 3.1.30; for example EC.3.1.30.1 or EC.3.1.30.2) and/or 3'-phospho(mono/oligo)nucleotides /oligo)nucleotides (EC 3.1.31).

As indicated previously, the compositions currently known and developed are compositions comprising, for the most part, a endodeoxyribonuclecise (Dnase I) of class EC 3.1.21 to hydrolyze DNA and/or a polysaccharide hydrolase (Dispersine B) to hydrolyze the polysaccharides present in the matrix of biofilms.

The enzymatic pharmaceutical composition used according to the present invention meets very strict manufacturing conditions. The composition according to the present invention is manufactured in compliance with good manufacturing practices (cGMP) which are directives that have become mandatory in the pharmaceutical world, whether at the level of the production chain of a medicine or at the level of manipulations in the laboratory. These directives require production tracing and quality control to ensure the efficacy, purity and reproducible safety of a product for pharmaceutical use. In particular, the enzymatic composition according to the invention meets the pharmaceutical specifications in terms of harmlessness, quantities of endotoxin and microorganisms (virus, mycoplasma, bacteria) present, purity and absence of product of animal origin or antibiotic used in its manufacture. These specifications are the prerequisites for therapeutic use in the human body, whether for external or internal use.

It has in fact been identified according to the present invention that it was possible to produce such an enzyme in a Gram+ bacterial strain (or via any other fermentation process not involving Gram- bacteria), which does not produce endotoxin and whose production and purification complies with good manufacturing practices standards. Other production methods are of course possible, including Gram-bacteria, subject to an appropriate downstream purification process. For example, benzonase endonuclease also complies with good manufacturing practices standards.

The para-pharmaceutical composition comprising the nuclease (endoribonuclease; RNase) chosen from classes EC 3.1.30 (EC.3.1.30.1 or EC.3.1.30.2) or EC 3.1.31 must not specifically be of pharmaceutical grade. By extension, such a para-pharmaceutical composition can be a medical device such as a dressing or a toothpaste, and can therefore be a personal hygiene product, such as a lotion or a toothpaste.

In addition, and surprisingly, the use of the composition according to the invention allows a reduction in the biomass of biofilms originating from many bacterial strains (and even yeasts when subtilisin and/or glucanase are added) and thus allows the microbicidal agent to access the microorganisms present inside the biofilm for the treatment of the biofilm infection and potentiates thus its effect. The use of the composition according to the present invention creates a synergistic effect of the enzymatic composition and the microbicidal agent used.

Indeed, while other RNAses belonging to the EC4.6.1 classification, such as RNase I and RNase A (although existing on the market at pharmaceutical grade and therefore administrable to the body of a living being, in particular a mammal, more particularly a human being) have no effect on biofilm infections or a limited effect on certain types of biofilms only, it has surprisingly been demonstrated that an endoribonuclease chosen specifically from the class EC 3.1.30 (EC.3.1.30.1 or EC.3.1.30.2) or EC 3.1.31 makes it possible to drastically reduce the biomass of biofilms and thus to potentiate the microbial agent which, without this composition, is not capable of enter the biofilm and treat the infection, this for biofilms of varied strains of bacteria and with a non-specific use of the biofilm infection to be treated or treated.

The non-specific endoribonuclease activity of enzymes belonging to classes EC 3.1.30 (EC.3.1.30.1 or EC.3.1.30.2) or EC 3.1.31 makes it possible to digest DNA and RNA. Against all expectations, these enzymes lead to a drastic reduction in the biomass of the biofilms already when they are used alone in a formulation according to the present invention, the drastic reduction in the biomass of the biofilms being similar to that observed for the commercial multi-enzymatic formulation. EnziQure®. In addition, according to the present invention, an effectiveness against several types of biofilms is already achieved with a single enzyme, which is particularly advantageous in a para-pharmaceutical or pharmaceutical composition where the least ingredient is sought. possible to facilitate marketing authorizations.

The dependent claims refer to other advantageous forms of use. According to a first use of a composition according to the present invention, the treatment and/or prevention of bacterial infections involving the formation of biofilm is a curative or preventive treatment of dermatological infections or of infections caused by superficial wounds or deep. These dermatological bacterial infections or those caused by superficial or deep wounds are, for example, wounds or burns. These infections can develop on chronic or acute wounds, burns, at the site of insertion of a medical device. The removal or reduction of biofilm speeds up the healing and healing process of wounds and burns.

According to a second use of a composition according to the present invention, the treatment and/or prevention of bacterial infections involving the formation of biofilm is a curative or preventive treatment of post-implantation infections associated with the infection of a medical device. implanted in the body or tissues around a medical device implanted in the body. The use of a composition according to the present invention will allow in situ treatment of the biofilm formed on an infected implanted medical device or on the tissues around said implanted medical device. For example, an infected implanted prosthesis should not be taken out of the human body to be cleaned. Infected internal tissues and the prosthesis can be cleared by in situ administration.

According to a third use according to the invention, the parapharmaceutical or pharmaceutical composition which can be administered to living beings, in particular to human beings in the treatment and/or prevention of bacterial infections involving the formation of biofilm is used for the manufacture of a treatment or in a personal or cosmetic hygiene treatment, such as for example a nail treatment, an oral solution, a mouthwash, a toothpaste, an eye bath, an eye lens cleaning solution, a solution cleaning of braces, dental prostheses, toothbrushes, anti-acne skin care.

According to another use according to the invention, the parapharmaceutical or pharmaceutical composition is used to clean the accessories in contact with the human body, for example piercings.

Advantageously, the composition further comprises a series of additional enzymes, for example one, two, three, four, five, six, seven, eight enzyme(s).

More particularly, an enzyme of said series of additional enzymes is chosen from the group consisting of glycosidases (EC 3.2.1), deoxyribonucleases (EC 3.1.21), oxidoreductases (EC 1.), hydrolases carboxylic ester (EC 3.1.1), proteases and peptidases (EC 3.4.), and mixtures thereof.

The class of glycosidases includes polysaccharide hydrolases such as cellulase (EC 3.2.1.4), glucanase (eg (3 1,3 endoglucanase, such as for example EC.3.2.1.39, CAS 9025-37-0, CAS 37340- 57-1, especially CAS 144941-36-6, which is (31,3 endoglucanase from Bacillus subtilis; endoglucanase is also called "Lyticase"), dispersin B (EC 3.2.1.52), hexosaminidase (EC 3.2. 1.52), alpha-amylase (EC 3.2.1.1), mannanase (EC 3.2.1.78 and EC 3.2.1.101), hyaluronidase (EC 3.2.1.35), glucosidase (EC 3.2.1.21 and EC 3.2.1.20), galactosidase (EC 3.2.1.22 and EC 3.2.1.23), chitinase (EC 3.2.1.14), chitosanase (EC 3.2.1.132), fructanase (EC 3.2.1.80), dextranase ( EC 3.2.1.11), lysozyme (EC 3.2.1.17) and pectinase (EC 3.2.1.15) This class also includes polysaccharide lyases such as alginate lyase (EC 4.2.99.4 and EC 4.2.2.26) and l hyaluronate lyase (EC 4.2.2.1).

The class of oxidoreductases includes, for example, laccase (EC

1 .10.3.2), peroxidases (EC 1 .1 1 .1 ) lactoperoxidase (EC 1 .1 1.1 .7), haloperoxidase (EC 1 .1 1 .2.1 ), myeloperoxidase (EC 1.1 1 .2.2) and glucose oxidase (EC 1.1.3.4).

The class of carboxylic ester hydrolases (EC 3.1.1) includes for example lipase (EC 3.1.1.3).

The class of proteases and peptidases (EC 3.4.) includes for example flavorzyme or proteases such as BlazeOPro, subtilisin (EC 3.4.21.62), bromelain (EC 3.4.22.33), collagenase (EC 3.4.24.3), papain (EC

3.4.22.2), trypsin (EC 3.4.21.4) and proteinase K (EC 3.4.21.64). Subtilisin is preferred.

A related aspect of the present invention is moreover the use of subtilisin for the (parapharmaceutical) treatment of a biofilm comprising Candida sp., such as Candida albicans. The subtilisin can be applied alone, or in association with the other enzymes above, either in sequential use (subtilisin then one or more other enzymatic activities or one or more enzymatic activities, followed by the subtilisin), or combined.

Conversely a related aspect of the present invention is subtilisin for the treatment of biofilm comprising Candida sp. , such as Candida albicans . in a patient. Subtilisin can be administered alone, or in combination with the other enzymes above, either in sequential use (subtilisin then one or more other enzymatic activities or one or more enzymatic activities, followed by subtilisin), or combined.

Thus, a related aspect of the present invention is a method of treating a biofilm comprising Candida sp., such as Candida albicans, the method comprising the following steps:

- the biofilm is reacted with the subtilisin;

- an antifungal is applied (administered).

This method advantageously comprises the following additional steps of applying one or more other enzymatic activities to the biofilm and/or of applying (administering) an anti-infective, for example an antibiotic.

In a preferred embodiment of the use of a composition according to the present invention comprising enzymes belonging to classes EC 3.1.30 (EC.3.1.30.1 or EC.3.1.30.2) and/or EC 3.1.31, or subtilisin, the composition comprises at least one second enzyme chosen from the group of glycosidases (EC 3.2.1).

In another preferred embodiment of the use of a composition according to the present invention comprising enzymes belonging to classes EC 3.1.30 (EC.3.1.30.1 or EC.3.1.30.2) or subtilisin, the composition comprises at least one third enzyme selected from the group consisting of glycosidases (EC 3.2.1), deoxyribonucleases (EC 3.1.21), oxidoreductases (EC 1), carboxylic ester hydrolases (EC 3.1.1), peptidases and proteases (EC 3.4), and their mixture, in particular chosen from the group consisting of glycosidases (EC 3.2.1) and peptidases (EC 3.4) (the addition of a peptidase is not preferred when the enzyme according to the invention is subtilisin).

In another preferred embodiment of the use of a composition according to the present invention comprising enzymes belonging to classes EC 3.1.30 (EC.3.1.30.1 or EC.3.1.30.2) or subtilisin, the composition comprises at at least a fourth enzyme selected from the group consisting of glycosidasesfEC 3.2.1 ), deoxyribonucleasesfEC 3.1.21 ), oxidoreductases (EC 1 ), carboxylic ester hydrolasesfEC 3.1.1 ), proteases and peptidases (EC 3.4) (the addition of a protease or a peptidase is not preferred when the enzyme according to the invention is subtilisin) for the manufacture of a medicament for the treatment and/or prevention post-implantation diseases associated with infection of a medical device implanted in the body.

In one embodiment of the use of a composition according to the present invention, the medical device is an orthopedic implant.

In a particular use of the composition according to the present invention, the treatment and/or prevention of bacterial infections involving the formation of biofilm is a curative or preventive treatment of a bacterial infection of tissues surrounding an implanted orthopedic implant or implanted orthopedic implant.

When the subtilisin and/or the lyticase ((3 1,3 endoglucanase) is present in the composition according to the invention, or added, the composition according to the invention is used (also) for the treatment and/or the prevention of Candida sp infection (Candida albicans) involved in biofilm, including mixed biofilms comprising Candida and one or more bacterial species, which are the most difficult biofilms to treat.

In another particular use of the composition according to the present invention, the treatment and/or prevention of bacterial infections involving the formation of biofilm is a curative or preventive treatment of a bacterial infection of tissues surrounding an implanted dental implant or of the implanted dental implant.

In yet another particular use of the composition according to the present invention (comprising enzymes belonging to classes EC 3.1 .30 (EC.3.1.30.1 or EC.3.1 .30.2), the treatment and/or prevention of bacterial infections involving biofilm formation is a curative or preventive treatment for bacterial infection of tissues surrounding a catheter, cannula, probe, prosthesis, endosseous implant, zygomatic implant, orthodontic implant, dental prosthesis, plate retainer, a valve, a drain, a stent, a tube for artificial respiration or an implanted screw or a catheter, a cannula, a probe, a prosthesis, an endosseous implant, a zygomatic implant, an orthodontic implant, a dental prosthesis, a plate of contention, a volva, a drain, a stent, an artificial respiration tube or an implanted screw.

Alternatively for the composition according to the present invention comprising subtilisin, the treatment and/or prevention of infections comprising Candida Sp. (Candida albicans) involving the formation of biofilm is a curative or preventive treatment of a fungal infection (potentially in addition bacterial infection) of tissues surrounding a catheter, a cannula, a probe, a prosthesis, an endosseous implant, a zygomatic implant, an orthodontic implant, a dental prosthesis, a contention plate, a valve, a drain, a stent, a tube for artificial respiration or an implanted screw or a catheter, a cannula, a probe, a prosthesis, an endosseous implant, a zygomatic implant, an orthodontic implant, a dental prosthesis, a contention plate, a valve, a drain, a stent, an artificial respiration tube or an implanted screw.

In an advantageous use of the composition according to the present invention (comprising enzymes belonging to classes EC 3.1 .30 (EC.3.1 .30.1 or EC.3.1 .30.2), the treatment and/or the prevention of bacterial infections involving the formation of biofilm comprises an application of said composition on a wound, an infection, tissues or a medical device, preferably an application of a woven or non-woven support impregnated with said parapharmaceutical or pharmaceutical composition.

The support can be a foam, a sponge, a film, a hydrocolloid dressing, a dressing based on alginate, polyurethane, a hydrogel, a gauze pad, a bandage, a wipe, a dressing, ...

In another advantageous use of the composition according to the present invention (comprising enzymes belonging to classes EC 3.1.30 (EC.3.1.30.1 or EC.3.1.30.2) and/or subtilisin), the treatment and/or prevention bacterial infections involving the formation of a biofilm comprises an application of said composition to a wound, an infection, tissues, preferably an application of a dressing in the form of a gel comprising said para-pharmaceutical or pharmaceutical composition. In another advantageous use of the composition according to the present invention (comprising enzymes belonging to classes EC 3.1.30 (EC.3.1.30.1 or EC.3.1 .30.2)), the treatment and/or prevention of bacterial infections involving the biofilm formation comprises an application of said composition to a wound, infection, tissues or a medical device, preferably an application of an aqueous, preferably buffered solution of said para-pharmaceutical or pharmaceutical composition, by infiltration, by irrigation, by injection, by percutaneous application, by inhalation, by mouthwash or eyewash, by dabbing.

The aqueous solution of said para-pharmaceutical or pharmaceutical composition according to the present invention is for example in concentrated form or in diluted form and/or ready for use.

In yet another advantageous use of the composition according to the present invention (comprising enzymes belonging to classes EC 3.1.30 (EC.3.1.30.1 or EC.3.1.30.2) and/or subtilisin), the treatment and/or the prevention of bacterial infections involving biofilm formation comprises an application of said composition to a wound, infection, tissues or a medical device, preferably an application of a paste or a viscous solution comprising said para-pharmaceutical composition or pharmaceutical, such as a toothpaste.

Advantageously, according to the present invention, said microbicidal agent, in particular said antibiotic, phage, antifungal or said disinfectant and said composition form a combination product for simultaneous, separate or staggered use over time.

Other embodiments of the use of a parapharmaceutical or pharmaceutical composition which can be administered to living beings, in particular to human beings, according to the present invention are indicated in the appended claims.

The present invention also relates to a parapharmaceutical or pharmaceutical composition that can be administered to living beings, in particular to human beings, comprising at least one endoribonuclease enzyme chosen from classes EC 3.1.30, more particularly from class EC 3.1.30.2 , and EC 3.1.31 , preferably at a content of 10 to 1000U/ml, preferably 50 to 500U/ml, of preferably from 100 to 500 U/ml, such as for example from 200 U/ml to 650 U/ml, more particularly from 250 U/ml to 550 U/ml, preferably from 300 U/ml, or even from 350 U/ml at 500 U/ml and optionally one or more pharmaceutically acceptable excipients. This has the advantage that the enzyme endoribonuclease has activity on RNA and DNA and allows digestion of the biofilm matrix, which can thus potentiate the effect of a microbicidal agent while allowing use of a limited number of enzymes.

Advantageously, said at least one endoribonuclease enzyme of the para-pharmaceutical or pharmaceutical composition according to the present invention is of bacterial origin. Particularly advantageously, the endoribonuclease enzyme originates from Serratia marcescens.

In a preferred embodiment, the composition according to the present invention further comprises a series of additional enzymes, for example one, two, three, four, five, six, seven, eight enzyme(s).

Advantageously, the composition according to the present invention comprises an enzyme from said series of additional enzymes of said composition is chosen from the group consisting of glycosidases (EC 3.2.1), deoxyribonucleases (EC 3.1.21), oxidoreductases (EC 1), carboxylic ester hydrolases (EC 3.1.1) and peptidases (EC 3.4), and their mixture

More particularly, according to the present invention, the composition comprises at least one second enzyme chosen from the group of glycosidases (EC 3.2.1), for example dispersin B, a cellulase or an endoglucanase ((3 1,3 endoglucanase, lyticase) .

In a preferred embodiment, the composition according to the present invention further comprises at least one third enzyme chosen from the group comprising glycosidases (EC 3.2.1), deoxyribonucleases (EC 3.1.21), oxidoreductases (EC 1 ), carboxylic ester hydrolases (EC 3.1 .1 ), peptidases and proteases (EC 3.4), for example dispersin B, a cellulase or a glucanase ((3 1 ,3 endoglucanase, lyticase) and a protease , such as subtilisin, or two enzymes chosen from, for example, dispersin B, a cellulase and glucanase ((3 1,3 endoglucanase, lyticase). In a preferred embodiment, the composition according to the present invention comprises at least a fourth enzyme chosen from the group comprising glycosidases (EC 3.2.1), deoxyribonucleases (EC 3.1.21), oxidoreductases (EC 1), carboxylic ester hydrolases (EC 3.1.1); peptidases and proteases (EC 3.4), for example dispersin B, a cellulase and glucanase ((3 1,3 endoglucanase, lyticase), or a protease, such as subtilisin and two enzymes chosen from dispersin B, a cellulase and glucanase ((3 1 ,3 endoglucanase, lyticase).

In a preferred embodiment, the composition according to the present invention comprises at least a fifth enzyme chosen from the group comprising glycosidases (EC 3.2.1), deoxyribonucleases (EC 3.1.21), oxidoreductases (EC 1), carboxylic ester hydrolases (EC 3.1.1), peptidases and proteases (EC 3.4), for example a protease, such as subtilisin, and dispersin B, a cellulase and glucanase ((3 1,3 endoglucanase, lyticase).

In a preferred embodiment, the composition according to the present invention comprises at least one sixth enzyme chosen from the group comprising glycosidases (EC 3.2.1), deoxyribonucleases (EC 3.1.21), oxidoreductases (EC 1), carboxylic ester hydrolases (EC 3.1.1), peptidases and proteases (EC 3.4).

In a preferred embodiment, the composition according to the present invention comprises at least a seventh enzyme chosen from the group comprising glycosidases (EC 3.2.1), deoxyribonucleases (EC 3.1.21), oxidoreductases (EC 1), carboxylic ester hydrolases (EC 3.1.1), peptidases and proteases (EC 3.4).

In a preferred embodiment, the composition according to the present invention comprises at least one eighth enzyme chosen from the group comprising glycosidases (EC 3.2.1), deoxyribonucleases (EC3.1.21), oxidoreductases (EC1), hydrolases carboxylic ester (EC3.1.1), peptidases and proteases (EC 3.4).

In a preferred embodiment, the composition according to the present invention further comprises at least one microbicidal agent such as an antibiotic, an antifungal, an antiseptic, one or more microbicidal peptides or phages, or an antibiotic and an antifungal, packaged separately or together with said endoribonuclease.

Preferably, the microbicidal molecule is chosen from the group consisting of fluoroquinolones, glucopeptides, lipoglucopeptides, fusidic acid, penicillins, cephalosporins, carbapenems, monobactams, polymixins, beta-lactams, macrolides , lincosamides, oxazolidinones, phenicols, tetracyclines, aminoglycosides, rifamycins, nitrofurans, sulfonamides, nitroimidazoles antifungals (echinocandins, fluorocytosins, azoles, griseofulvins, amphotericin), lytic enzymes (e.g. endolysins or lysozyme), N-acetylcysteine, quaternary ammonia, biguanides, amines, amidines, halogenated derivatives (including chlorhexidine in particular), microbicidal peptides, silver derivatives (Ag), H 202, peracids, phenolic derivatives, aldehydes, alcohols, phages and mixtures thereof.

In another preferred embodiment, the composition according to the present invention further comprises a quorum sensing inhibitor.

It is also possible to provide, as additional compounds, one or more enzymes which inhibit “quorum sensing” within the biofilms. Quorum sensing is a means of communication between bacterial cells that allows them to coordinate action across the entire population. Quorum sensing regulates, among other things, the formation of biofilms (generally early stages), based on the secretion and diffusion of acyl homoserine lactone (in Gram-) or peptides (in Gram+), which are specifically recognized by cells of the same population. In particular, mention may be made of acylase I and 2(5H)-furanone.

In a preferred embodiment, the composition according to the present invention further comprises an enzymatic buffer chosen from the group consisting of Tris-HCl, TGN, TBS, PBS, HEPES, MES, PIPES, MOPS, BES, TES, phosphate buffer and citrate buffer, containing or not 0 to 2 mM MgCl2, containing 0 to 2 mM CaCl2, and 0 to 500 mM NaCl.

In another preferred embodiment, the composition according to the present invention further comprises an enzymatic buffer comprising 0 to 50% of stabilizing agent (polyol, arginine, calcium formate, glucose). In a preferred embodiment, the composition according to the present invention further comprises at least one surfactant.

In a preferred embodiment, the composition according to the present invention additionally comprises at least one preservative and/or one sequestrant and/or one dispersant.

In a preferred embodiment, the parapharmaceutical or pharmaceutical composition according to the present invention is in the form of a solution, for example a mouthwash, an eye bath, a lotion, an irrigating solution, a cleaning solution for dental prostheses , toothbrushes.

In another preferred embodiment, the composition is a hydrophilic dressing, for example a hydrogel.

In a variant according to the present invention, the composition is in immobilized form on a woven or nonwoven, dry support or on a medical device or in impregnated form on a woven or nonwoven support.

In another advantageous variant of the present invention, the composition is in the form of a topical composition.

In yet another advantageous variant of the present invention, the composition is in the form of a sterile solution which can be administered by infiltration, by irrigation, by injection, by percutaneous application and by inhalation.

The present invention also relates to a parapharmaceutical or pharmaceutical composition, for use as a potentiator of a microbicidal agent, in particular an antibiotic, an antifungal, or a disinfectant, in the treatment and/or prevention of bacterial infections involving biofilm formation.

In a particular embodiment according to the present invention, the para-pharmaceutical or pharmaceutical composition is intended for use in the treatment and/or prevention of bacterial infections involving the formation of biofilm is treatment and/or prevention of infections acute or chronic dermatological conditions or infections caused by superficial or deep wounds (burns and/or wounds). In a particular embodiment according to the present invention, the para-pharmaceutical or pharmaceutical composition is intended for use in the curative and/or preventive treatment of post-implantation infections associated with the infection of tissues around a medical device implanted in the body or a medical device implanted in the body.

In an advantageous embodiment according to the present invention, the para-pharmaceutical or pharmaceutical composition is intended for use in a body or cosmetic hygiene care, such as for example a care for the nails, an oral solution, a mouthwash , toothpaste, eye bath, eye lens cleaning solution, anti-acne skin care.

In another advantageous embodiment according to the present invention, the para-pharmaceutical or pharmaceutical composition is intended for use in a curative or preventive treatment of a bacterial infection of tissues surrounding an implanted orthopedic implant or the implanted orthopedic implant.

In another advantageous embodiment according to the present invention, the para-pharmaceutical or pharmaceutical composition is intended for curative or preventive treatment of a bacterial infection of tissues surrounding an implanted dental implant or of the implanted dental implant.

In another advantageous embodiment according to the present invention, the para-pharmaceutical or pharmaceutical composition is intended for use in a curative or preventive treatment of a bacterial infection of tissues surrounding a catheter, a cannula, a probe, a prosthesis, an endosseous implant, a zygomatic implant, an orthodontic implant, a dental prosthesis, a retainer plate, a valve, a drain, a stent, a tube for artificial respiration or an implanted screw or else a catheter, a cannula , a probe, a prosthesis, an endosseous implant, a zygomatic implant, an orthodontic implant, a dental prosthesis, a contention plate, a valve, a drain, a stent, a tube for artificial respiration or an implanted screw. In yet another advantageous embodiment according to the present invention, the para-pharmaceutical or pharmaceutical composition is intended for use in the treatment and/or prevention of bacterial infections involving the formation of biofilm which comprises an application of said composition on a wound, an infection, tissues or a medical device, preferably an application of a woven or non-woven support impregnated with said para-pharmaceutical or pharmaceutical composition or on which said para-pharmaceutical or pharmaceutical composition is immobilized, dry.

In yet another advantageous embodiment according to the present invention, the para-pharmaceutical or pharmaceutical composition is intended for use in the treatment and/or prevention of bacterial infections involving the formation of biofilm which comprises an application of said composition on a wound, an infection, tissues, preferably an application of a dressing in the form of a gel, more particularly a hydrogel comprising said para-pharmaceutical or pharmaceutical composition.

In a variant according to the present invention, the parapharmaceutical or pharmaceutical composition is intended for use in the treatment and/or prevention of bacterial infections involving the formation of a biofilm which comprises an application of said composition to a wound, an infection, tissues, preferably an application of a dressing in gel form, more particularly a hydrogel comprising said parapharmaceutical or pharmaceutical composition.

In a variant according to the present invention, the parapharmaceutical or pharmaceutical composition is intended for use in the treatment and/or prevention of bacterial infections involving the formation of a biofilm which comprises an application of said composition to a wound, an infection, tissues or a medical device, preferably an application of an aqueous solution, preferably buffered, of said parapharmaceutical or pharmaceutical composition, by infiltration, by irrigation, by injection, by percutaneous application, by inhalation, by mouthwash or eye bath, by buffering, by soaking bath.

In another variant according to the present invention, the para-pharmaceutical or pharmaceutical composition is intended for use in the treatment and/or prevention of bacterial infections involving biofilm formation which comprises application of said composition to a wound, infection, tissue or medical device, preferably application of a paste or viscous solution comprising said parapharmaceutical or pharmaceutical composition, such as for example a toothpaste.

In yet another variant according to the present invention, the para-pharmaceutical or pharmaceutical composition is intended for use as a combination product for simultaneous, separate or staggered use over time.

Finally, the composition according to the present invention is intended for surgical use.

Other embodiments of the parapharmaceutical or pharmaceutical composition according to the invention are indicated in the appended claims.

Other characteristics, details and advantages of the invention will become apparent from the description given below, on a non-limiting basis and with reference to the drawings and the examples.

FIG. 1 is a graph which illustrates the reduction in the percentage of biomass of the biofilm of several strains of Staphylococcus aureus, following contact with a composition according to the invention with a concentration of 500 U/ml for denarase.

FIG. 2 is a graph which illustrates the reduction in the percentage of biomass of the biofilm formed by different strains of S. aureus and Staphylococcus epidermidis, following contact with a composition according to the invention with a concentration of 100 U/ml for denarase in comparison with a composition comprising 100 U/ml of RNase I, with a composition comprising 100 U/ml for each enzyme of a mixture of RNase 1, RNase A and DNase 1.

Figure 3 is a series of four graphs which illustrates the decrease in the percentage of biofilm biomass of different strains of S. aureus and S. epidermidis, following contact with a composition according to the invention with a concentration of 500 U /ml for denarase compared to a composition comprising a CDD enzymatic cocktail comprising 500 U/ml of denarase, 0.06 U/ml of dispersin B and 7 U/ml of cellulase, in comparison with a composition comprising 0.06 U/ml of dispersin B, in comparison with a composition comprising 7 U/ml cellulase.

Figure 4 is a series of three graphs which illustrates the decrease in the percentage of biomass of the biofilm of multiple strains of S. aureus and S. epidermidis, following contact with a composition comprising only 500 U/ml of denarase, in comparison with a composition comprising an enzymatic cocktail comprising 500 U/ml of denarase and 0.06 U/ml of dispersin B, in comparison with a composition comprising an enzymatic cocktail comprising 500 U/ml of denarase and 7 U/ml of cellulase.

Figure 5 is a series of two graphs that illustrates the decrease in percent biofilm biomass of different strains of p. aeruginosa, following contact with a composition comprising 500 U/ml of denarase, in comparison with a composition comprising a CDD enzymatic cocktail comprising 500 U/ml of denarase, 0.06 U/ml of dispersin B and 7 U/ml of cellulase.

Figure 6 is a series of 4 graphs which illustrates the decrease in viability (expressed log10 (CFU/ml) of the biofilm of S. aureus ATCC33591 after a curative treatment of the biofilm with a composition according to the invention comprising denarase at 500 U/ml followed by 24 hours of incubation with different vancomycin concentrations of 0, 10, and 20 mg/L, as well as the reduction in the biomass (expressed in absorbance at 570nm) of the biofilm of S. aureus ATCC33591 after a curative treatment biofilm with a composition according to the invention comprising denarase at 500 U/ml followed by 24 hours of incubation with different vancomycin concentrations of 0, 10 and 20 mg/L.

Figure 7 is a series of 3 graphs which illustrates the viability in the biofilm of S. aureus ATCC33591 expressed in logio (CFU/ml) after a curative treatment of the biofilm with a composition comprising a CDD enzymatic cocktail comprising 500 U/ml of denarase , 7 U/ml of cellulase and 0.06 U/ml of dispersin B followed by 24 hours of incubation with 0 mg/L or 20 mg/L of vancomycin, in comparison with a composition comprising a BDD enzymatic cocktail comprising 500 U/ml of denarase , 1% v/v of BlazePro and 0.06 U/ml of Dispersine B followed by 24h incubation with 0 mg/L or 20 mg/L of vancomycin, in comparison with a composition comprising an FDD enzymatic cocktail comprising 500 U/ml of denarase, 1% v/v of Flavorzyme and 0.06 U/ml of Dispersine B followed by 24h incubation with 0 mg/L or 20mg/L of vancomycin.

FIG. 8 represents the effect of different concentrations of vancomycin (0 and 20mg/L) on the viability expressed in log10 (CFU/ml) on the biofilm of different strains of S. aureus and S. epidermidis after a curative treatment with different tri-enzyme compositions. The CDD tri-enzymatic composition comprises an enzymatic cocktail composed of 7 U/ml of cellulase, 0.06 U/ml of dispersin B and 500 U/ml of denarase, in comparison with a CDD2 enzymatic composition comprising a tri-enzymatic cocktail composed of 70 U/ml of cellulase, 0.32 U/ml of dispersin B and 500 U/ml of denarase, in comparison with an ADD enzymatic composition comprising a tri-enzymatic cocktail composed of 70 U/ml of cellulase, 2000 U/ml alpha-amylase and 500 U/ml denarase.

FIG. 9 represents the effect of 20 mg/L of vancomycin on the biomass expressed in % and the viability expressed in log10 (CFU/ml) of the biofilm of different strains of S. aureus and S. epidermidis formed in the presence of compositions according to the invention. The CDD2 tri-enzymatic composition comprises a tri-enzymatic cocktail composed of 70 u/ml of cellulase, 0.32 U/ml of dispersin B and 500 U/ml of denarase; in comparison with an ADD enzymatic composition comprising a tri-enzymatic cocktail composed of 70 U/ml of cellulase, 2000 U/ml of alpha-amylase and 700 U/ml of denarase.

Figure 10 represents the effect of different concentrations of vancomycin (0 and 20mg/L) on the viability expressed in log10 (CFU/ml) of the biofilm of S. aureus ATCC33591 and S. epidermidis ATCC35984_formed in the presence of compositions according to the invention . The CDD enzymatic composition comprising a tri-enzymatic cocktail composed of 7 U/ml of cellulase, 0.06 U/ml of dispersin B and 500 U/ml of denarase; The CDD2 enzymatic composition comprising a tri-enzymatic cocktail composed of 70 U/ml of cellulase, 0.32 U/ml of dispersin B and 500 U/ml of denarase; in comparison with an ADD enzymatic composition comprising a tri-enzymatic cocktail composed of 70 U/ml of cellulase, 2000 U/ml of alpha-amylase and 500 U/ml of denarase. In the figures, identical or similar elements bear the same references.

Other characteristics and advantages of the present invention will be drawn from the non-limiting description which follows, and with reference to the drawings and the examples.

Efficacy of a composition according to the invention for reducing the biomass of biofilms involved in infections of the human body

In order to test the effectiveness of a composition according to the invention, comprising at least one endoribonuclease enzyme, several experiments were carried out on different bacterial strains (clinical isolates and ATCC collection strains) (Table 1).

Table 1.-

The effect of a treatment with the composition according to the invention on the biomass of the biofilms was studied in a static model in 96-well plates. The curative enzymatic treatment is carried out on a preformed 24-hour biofilm. To test its effectiveness in reducing the biomass of biofilms, the composition according to the invention is brought into contact with the biofilm for 1 hour at 37°C. The enzyme solution is then removed, and the detached biomass is removed by washing steps. Crystal violet (CV) dye is then used to quantify residual biomass. This the latter interacts with dead and living cells, and macromolecules of the extracellular matrix of the biofilm (such as DNA and exopolysaccharides). The CV labeling is quantified by spectrophotometry by measuring the absorbance at 570 nm.

1.1 method of culture, enzymatic treatment, quantification of biomass and analysis of results

The different strains of S. aureus and P. aeruginosa (Table 1) were inoculated in 5ml of TGN culture medium (Tryptic Soy Broth VWR + 1% glucose + 2% NaCI) from 20 μl of a stored glycerol stock at -80°C. The strains were then incubated at 130 rpm aerobically at 37°C. After 18 h of growth, the precultures were diluted in TGN to reach an optical density at 620 nm (OD 62 O) of 0.05, which corresponds to +/- 5*10 ⁶ CFU/ml. Two hundred microliters of each culture (n=4 for each condition tested) were placed in the wells of a 96-well plate and incubated at 37° C. without shaking for 24 hours to allow the formation of the biofilm. The biofilms are then washed 2× with 200 μl PBS pH 7.5 (Sigma) in order to eliminate the planktonic cells (ie non-adherent to the biofilm). The composition according to the invention or the control compositions CT- (negative control) and CT+ (positive control) (200 μl) are added to the washed biofilm and the biofilm is incubated for 1 h at 37° C. (n=4 for each condition). The plates are then emptied, the biofilm is washed 2X with 200 μl PBS pH 7.5 (Sigma) and dried at 60° C. for 18 h before analyzing the biomass.

To quantify the residual biomass, a 1% CV solution (Sigma) is added to the biofilms at ambient temperature for 15'. The unfixed dye is then washed off with distilled water. The dye attached to the biofilm is then detached and dissolved with 66% peracetic acid and the absorbance at 570 nm (Aszo) is measured in a SpectraMax M3 multimode reader. This absorbance value corresponds to the biomass of the biofilm.

To analyze the effect of the compositions according to the invention, a statistical test (one-way ANOVA and Tukey's post-hoc test) is carried out by comparing the absorbance values of the untreated biofilms (negative control, CT-=treatment with buffer without enzyme) and biofilms treated with the enzymatic compositions including a positive control, CT+. This positive control includes a dye, two non-anionic surfactants, a sequestrant, a preservative, an enzymatic stabilizer, a solvent, seven enzymes including two proteases (EC 3.4), a laccase (EC 1 .10.3.2), a mannanase ( EC 3.2.1.78 and EC 3.2.1.101), an amylase (EC 3.2.1.1) and a lipase (EC 3.1.1.3). The difference is significant when the pvalue of the statistical test is less than or equal to 0.05 (* character represented on the graphs). When this is specified in the comparative examples, the activity of the enzymatic compositions are compared with each other (one-way ANOVA and post-hoc Tukey test).

J.2 Results

Example 1.-composition according to the invention containing denarase in TGN.

First, a composition comprising denarase (c-Lecta), which is an endoribonuclease of S. marcescens belonging to the enzymatic class EC 3.1.30, was tested at a concentration of 500 U/ml in TGN. The negative control (CT-) is composed of TGN only. The Aszo absorbance of the CV measured on the CT- corresponds to 100% biomass. As shown in Figure 1, the biomass percentage of a biofilm of S. aureus ATCC 29213, ATCC 33591, 7832, 7841, 1 142-004 and 1 144-20 decreases by 75%, 76%, 72% respectively, 71%, 47% and 52%. Statistical analysis (ANOVA and Tukey's post-hoc test indicates that in all cases this difference is significant (pvalue < 0.05) compared to the CT-. This decrease suggests that the effect of a microbicidal agent will be potentiated after treatment of the biofilm with denarase, comparison of the efficacy of the composition of example 1 with other endoribonucleases.

The effect on denarase biomass was compared to those of a negative control (TGN), a positive control (EnziQure ^R 1% in TGN; OneLife sa), and compositions containing RNase I only (Escherichia coll endoribonuclease; class EC4.6.1; ThermoFisher Scientific), and a mixture of RNase I, RNase A (bovine endoribonuclease class EC 4.6.1; ThermoFisher Scientific) and DNase I (bovine endodeoxyribonuclease class EC 3.1 .21 ; ThermoFisher Scientific).

The compositions are listed in Table 2.

Table 2.-

These tests were carried out with the aim of comparing the disruptive effect on biofilms of the various nucleases at 100 U/ml in TGN. These compositions were tested on a 24-hour biofilm of S. aureus ATCC33591 and 7832, and S. epidermidis ATCC35984 (n=4) by following the protocol described in point 1.1.1.

FIG. 2 shows that RNase I (endoribonuclease) according to comparative example EC1 has little or no significant effect on the reduction in the percentage of biomass of the biofilms (1 biofilm/3 is significantly reduced compared to CT-). The addition of RNase A (endoribonuclease) and DNase I (endodeoxyribonuclease) in addition to RNase I according to comparative example EC2 slightly improves the disruptive activity of the composition of comparative example EC1 A (2 biofilms/3 are significantly reduced). Interestingly, denarase (example 1) (endoribonuclease) significantly reduces the biomass of 2 biofilms/3, like the EC2 nuclease mixture, but more effectively: 46% vs. 30% for the ATCC33591 strain and 37% vs 13% for the ATCC35984 strain. Given that the aspecific endoribonuclease activity of denarase makes it possible to digest both DNA and RNA, it is unexpected to find that an endoribonuclease specifically chosen from the EC 3.1.30 or EC 3.1.31 class allows a more effective reduction of biofilm biomass than a DNase I - RNase I - RNase A mixture. The scientific reasons for this observation are not known to date.

1.2.3 comparison of the efficacy of denarase in curative treatment with other enzymatic compositions

The anti-biomass activity in curative treatment of denarase (500U/ml) was then compared with that of cellulase (Sigma; 7U/ml) and dispersin B (GIGA; 0.06 U/ml), and to that of a tri-enzymatic cocktail composed of denarase, cellulase and dispersin B at the same concentrations. These 4 compositions (Exl, EC3, EC4 and Ex 2) were tested on the biofilms of S. aureus ATCC33591, ATCC29213 and S. epidermidis ATCC35984 following the protocol detailed in point 1.1.1, except that the mixtures were made in a 20mM Tris-HCl buffer pH 7. In this experiment, the CT- is 20 mM Tris-HCl pH 7 without enzyme and its biomass corresponds to 100%. The CT+ is composed of 1% EnziQure ^R in this same buffer. The compositions are listed in Table 3.

Table 3.-

It can be seen in Figure 3 that the composition comprising denarase (Ex.2) is the composition (Figure 3A) allowing the greatest reduction in the biomass of each of the biofilms with a significant reduction and greater than 80% in the biomass of the 3 biofilms tested (Figure 3A). Cellulase (EC. 3) (Figure 3B) indeed has no significant effect and dispersin B (EC. 4) (Figure 3C) decreases biofilm from 70% (ATCC29213) to 27% (ATCC33591). The mixture of the 3 enzymes (Ex. 3) (FIG. 3D) is as effective as denarase alone (Ex.2) on 2 biofilms/3. However, the composition of Example 3 is less effective than the denarase of Example 2 on the biofilm of the strain ATCC29213. These results suggest that, under the experimental conditions tested, there is no synergistic effect between denarase, cellulase and dispersin B.

1.2.4 comparison of biomass disruptive activity

To confirm the absence of synergy between denarase, cellulase and dispersin B, the biomass disrupting activity of denarase ([Example 2 (Ex.2)] - (Figure 4A) was compared with that of duos enzymes denarase + dispersin B ([Example 4 (Ex.4)] - (Figure 4B) and denarase + cellulase - ([Example 5 (Ex.5)] (Figure 4C). The strains, experimental conditions and enzymatic concentrations used are the same as in the experiment described above. In this experiment, the CT- is 20 mM Tris-HCl pH 7 without enzyme and its biomass corresponds to 100%. The CT+ is composed of 1% EnziQure ^R in this same buffer. The compositions tested are listed in Table 4.

Table 4.-

Similar to what was observed previously, the results obtained indicate that the addition of dispersin B (Example 4 - Figure 4B) or cellulase (Example 3 - Figure 4C) does not increase the activity of the denarase of Example 2 significantly on the strains of staphylococci tested (FIG. 4A). We therefore do not observe any synergistic effect associated with the combination of denarase with cellulase or dispersin B.

1.2.5 comparison of disruptive activity on P. aeruginosa

The disruptive activity of the biofilm of denarase according to example 1 (500U/ml) and of a tri-enzymatic mixture according to example 6 composed of denarase (500U/ml), cellulase (7U/ml) and dispersin B (0.06U/ml) was tested on 3 strains of P. aeruginosa (PAO1, ATCC27853 and 618) as a curative treatment (TGN buffer). In this experiment, the CT- is the TGN without enzyme and its biomass corresponds to 100%. The CT+ is composed of 1% EnziQure ^R in this same buffer.

The compositions tested are listed in Table 5.

Table 5.-

The results presented in Figure 5 show that the denarase (Ex.l; Fig. 5B) and the tri-enzymatic composition of example 6 (Ex. 6; Fig. 5A) are also effective in reducing the biomass of the 3 biofilms tested with 94%, 85%, and 44% reductions in biofilm biomass of P. aeruginosa PAO1, ATCC27853, and 618, respectively, in the presence of denarase. No significant difference is observed between the 2 compositions. These results indicate that there is no synergy between denarase, cellulase and dispersin B to reduce the biomass of P. aeruginosa biofilms. Also, interestingly, the denarase and composition of Example 6 is more effective than the enziQure multi-enzyme detergent (CT+; contains 7 enzymes) in decreasing the biofilm biomass of P. aeruginosa 618.

Efficacy of a composition according to the invention in combination with a microbicide to reduce the biomass and the viability of the biofilms involved in infections of the human body

For the trials presented below, vancomycin was used as the antibiotic molecule. The antibiotic is added at different concentrations in TGN for 24 h at 37° C. on the biofilms pretreated with the enzymatic composition according to the invention (see the following sections). The biofilm is then washed before carrying out the biomass and viability measurements.

Two different biofilm models were used: static biofilm in 96-well plate (as described previously) and biofilm on titanium coupons. Titanium was chosen because it is a material widely used in the manufacture of implants (eg orthopedic prostheses, dental implants, heart valves, pacemakers, etc.). The techniques used to measure viability differ between the 2 models and are detailed below. 2.1 biofilm in 96-well plates

In this model, cell viability was measured indirectly, by measuring the metabolism of cells in the biofilm. Indeed, the viability was quantified by following the evolution of the color of resazurin (7-Hydroxy-3H-phenoxazin-3-one oxide) (prestoBlue, ThermoFisher). This blue colored compound turns pink when reduced to resorufin by the redox activity of the biofilm, activity which is directly proportional to the number of metabolically active cells in the biofilm. The quantification of resorufin is carried out by measuring the fluorescence. To correlate the number of cells present in the biofilm with the fluorescent signal, a calibration curve is produced in each experiment by measuring the fluorescent signal emitted by different known cell concentrations.

2.1.1 method of cultivation, enzymatic treatment,

The experimental method for cultivating the strains and forming the biofilm is described in point 1.1 of this document. After 24 hours of formation of the biofilm at 37° C. in the wells of the 96-well plate, the biofilm was washed 2X with PBS (200 μl) and treated for 1 h at 37° C. with the composition according to the invention or the compositions controls (CT- and CT+) (n= 4 for each condition tested). The biofilm is then washed 2X with PBS (200 μl). Two hundred microliters of different concentrations of vancomycin prepared in TGN are then added to the biofilm and the plate is incubated for 24 hours at 37°C. Biofilms that are not treated with vancomycin are incubated in the presence of TGN only. The biofilms are then washed 2X with PBS (200 μJ) before analyzing the biomass and the viability. The biomass is quantified by the CV staining technique following the procedure described in point 1.1. For the biomass analysis, the prestoBlue reagent (ThermoFisher) is diluted 10X in CA-MHB (VWR) culture medium and 200 μl are added to the wells. To perform the calibration line, the biofilm of two CT- samples not treated with enzymes or with vancomycin is detached and homogenized in 100 μl of CA-MHB and different dilutions of this sample are carried out in CA-MHB (from 10 to 10). Ten microliters of each dilution are then spread out on a TSA dish to carry out a bacterial count. One hundred microliters of a diluted 5X-CaMHB prestoBlue mixture is then added to the 90 μl of different dilutions. The plate containing all the samples is then incubated for 24 hours at 37°C in the spectraMax M3 plate reader. The fluorescence is measured every 10 minutes for 18 hours (excitation 560nm, emission 590nm).

To analyze the effect of the compositions according to the invention, a statistical test (one-way ANOVA and Tukey's post-hoc test) is carried out. This test compares the values of fluorescence (viability) or absorbance at 570 nm (biomass) of the negative control CT- (= treatment with buffer without enzyme) and of the biofilms treated with the enzymatic compositions, and this at each vancomycin concentration . The difference is significant when the pvalue of the statistical test is less than or equal to 0.05 (* character shown on the graphs). When this is specified in the comparative examples, the activity of the enzymatic compositions are compared with each other (one-way ANOVA and post-hoc Tukey test).

2.1.2 Results

FIG. 6 illustrates the potentiated effect of a microbicidal agent (vancomycin) by the composition of example 1 or of example 2 comprising denarase on the biofilm of S. aureus ATCC33591. The composition was tested in TGN (Ex. 1 - Figs. 6A and 60) and in 20 mM TrisHCl pH7 (Ex. 2 - Figs. 6B and 6D). The CT- and CT+ controls are composed of buffer without enzymes. CT+ controls are composed of 1% enziQure ^R (v/v) in buffer (TGN or 20mM TrisHCl). After enzymatic treatment for 1 h at 37° C., the biofilms were incubated for 24 h at 37° C. in the presence of the following concentrations of vancomycin: 0 mg/L, 10 and 20 mg/L.

The viability results obtained (Fig. 6A and 6B) show that in the absence of enzymatic treatment, vancomycin (10 mg and 20 mg/L) does not reduce (Fig. 5A) or very little (Fig. 5B) the biofilm viability of S. aureus ATCC33591. On the other hand, when the biofilm is pretreated with the denarase of example 1 (in TGN) and of example 2 (in 20 mM TrisHCl pH7), a significant reduction compared to the CT- of 1.35 logs and of 0.5 logs, respectively, is observed after treatment with 20mg/L of vancomycin. These decreases correspond to a decrease in viability of 96.5 and 80%, respectively, compared to the respective CT- controls without enzymes at 20 mg/L of vancomycin. The effect denarase potentiator on vancomycin 20mg/L is also observed on the biomass with a biomass reduction of 84% and 70% in TGN and Tris, respectively (Fig. 6C and 6D). A similar but lighter effect on the viability and the biomass is measured in the presence of 10 mg/L of vancomycin: reduction of 50% of the viability and 80% of the biomass in TGN, compared to CT-.

2.2 biofilm on titanium coupons

In this model, the viability is quantified after detachment and homogenization of the biofilm by the technique of spreading and counting the cells on a TSA culture dish (VWR).

2.2. 1 method of culture, enzymatic treatment, quantification of biomass and viability and analysis of results

The titanium coupons (n = 3 for each condition) are placed in the wells of a 12-well plate and are incubated at 37°C with shaking (50 rpm) for 24 hours in 3ml of bacterial inoculum at an OD of 0.005 ( 10 ⁶ CFU/ml) in order to allow the formation of biofilm. The coupons are then washed 2X with PBS (2ml) and treated for 1 h at 37° C. with the composition according to the invention or the solution without enzymes (CT−=20 mM TrisHCl pH7). The coupons are then washed 2X with PBS (2ml) and reincubated in 750 μl of TGN containing 0 or 20 mg/L of vancomycin for 24 hours at 37° C. with stirring (50 rpm). After 2 washes with PBS (2ml), the biofilm is unhooked and homogenized in 2ml of PBS. Different dilutions are made (from 10 to 10) and 10 μl of each dilution is spread on a TSA dish. The colonies (CFU) are counted after 18 hours of incubation at 37°C.

To analyze the effect of the compositions according to the invention, a statistical test (one-way ANOVA and Tukey's post-hoc test) is carried out. This test compares the fluorescence (viability) or absorbance (biomass) values of the negative control CT- (= treatment with buffer without enzyme) and of the biofilms treated with the enzymatic compositions, and this at each vancomycin concentration. The difference is significant when the pvalue of the statistical test is less than or equal to 0.05 (* character shown on the graphs). When this is specified in the comparative examples, the activity of the enzymatic compositions are compared with each other (one-way ANOVA and post-hoc Tukey test).

2.1.2 Results Potentiating effect of 3 tri-enzymatic compositions on the efficacy of vancomycin

Figure 7 illustrates the potentiating effect of three tri-enzymatic compositions containing denarase on the microbicidal effect of vancomycin at 20mg/L: (i) Example 8 (Ex. 8): cellulase (7U/ml), denarase (500U/ml) and dispersin B (0.06U/ml), (ii) Example 9 (Ex. 9): flavorzyme (1% v/v), denarase (500U/ml) and dispersin B (0.06 U/ml) and (iii) BDD: Blaze® Pro (1% v/v), denarase (500U/ml) and dispersin B (0.06U/ml) on S. aureus ATCC33591. The buffer used is 20 mM Tris-HCl pH7.

The compositions are listed in Table 6.

Table 6.-

The results show that in the absence of enzymatic treatment (CT-) vancomycin 20mg/L does not reduce the viability in the biofilm. On the other hand, the pretreatment of the biofilms with the 3 compositions significantly potentiate the effect of vancomycin. Indeed, with the 3 cocktails a similar reduction of 2.5 logs is observed in the presence of 20mg/L of vancomycin (= 99.8% reduction in viability).

Pofenfialisafeur effect of 3 fri-enzymafic compositions on vancomycin

Figure 8 illustrates the potentiating effect of three tri-enzymatic compositions containing denarase on the microbicidal effect of vancomycin at 20mg/L: (i) Example 6: cellulose (7U/ml), denarase (500U/ml) and dispersin B (0.06U/ml), (ii) Example 10: cellulose (70U/ml), denarase (500U/ml) and dispersin B (0.32 U/ml) and (iii) Example 11: alpha-amylase (2000 U/ml); cellulose (70U/ml), denarase (500U/ml) and dispersin B (0.32 U/ml). These cocktails were tested as a curative treatment on the biofilms of S. aureus ATCC33591 (Fig. 8A), S. epidermidis ATCC35984 (Fig. 8B) and S. aureus 144-20 (Fig. 8C). The buffer used is TGN.

The compositions are listed in Table 7.

Table 7.-

The results show that in the absence of enzymatic treatment (CT- ), vancomycin 20mg/L does not significantly reduce viability in the biofilm. On the other hand, the pretreatment of the biofilms with the 3 compositions significantly potentiates the effect of vancomycin on the viability of the 3 strains tested. Under these conditions, a reduction in viability of 2.5 to 3 logs is observed in the presence of 20 mg/L vancomycin compared with the CT- not treated with the cocktails.

Efficacy of a composition according to the invention in combination with a microbicide to prevent the formation of biofilm involved in infections of the human body

3.1 Biofilm model in 96-well plates The ability of the composition according to the invention to prevent the formation of biofilm was tested on a model of biofilm in a 96-well plate. In this experimental set-up, the enzymatic compositions are added to the starting bacterial inoculum (TGN medium containing 5*10 ⁶ CFU/ml), that is to say before the formation of the biofilm. After 24 hours of growth at 37° C., the biofilms are washed and incubated in the presence of vancomycin (20 mg/L) for 24 hours at 37° C., as described in point 2.1.1. The quantity of biomass (CV staining) and the viability (metabolism measurement) of the biofilms are then measured and compared to the CT- condition where the starting inoculum did not contain enzymes (n=4 in each condition).

The compositions tested are listed in Table 8.

Table 8.-

Figure 9 shows the preventive effect of 2 compositions according to the invention containing denarase (examples 10 & 11), on different strains of S. aureus and S. epidermidis. In the presence of 20 mg/L vancomycin, the 2 cocktails significantly reduce the quantity of biomass formed (Fig. 9A) and the viability of the biofilm (Fig. 9B), with variable amplitudes between the strains.

3.2 titanium coupon biofilm model

The preventive effect of the formation of biofilm of the compositions according to the invention were tested on a titanium coupon model. In this experiment, the coupons are incubated for 24 h at 37° C. with a bacterial inoculum (10 ⁶ CFU/ml) in TGN containing different enzymatic compositions, or not (=CT-). After formation of the biofilm, the coupons are incubated in the presence (Van Omg/L) or presence of 20 mg/L of vancomycin for 24 hours before analysis of viability by the technique of plating on TSA and counting.

The compositions tested are listed in Table 7.

Table 7.-

Figure 10 illustrates the preventive effect of three tri-enzymatic compositions containing denarase on the microbicidal effect of vancomycin at 20mg/L: (i) Example 6: cellulase (7U/ml), denarase (500U/ml) and dispersin B (0.06U/ml), (ii) Example 10: cellulase (70U/ml), denarase (500U/ml) and dispersin B (0.32 U/ml) and (iii) Example 1 1 : alpha-amylase (2000 U/ml); cellulase (70U/ml), denarase (500U/ml) and dispersin B (0.32 U/ml). These cocktails were tested as a preventive treatment on the biofilm of S. aureus ATCC33591 (FIG. 10A) and S. epidermidis ATCC35984 (FIG. 10B).

The results indicate that in the presence of vancomycin 20 mg/L, the 3 cocktails significantly reduce the viability in the biofilm formed by S. aureus ATCC33591 (decrease of 2.5 to 3 logs) (Fig. 10A) and S. epidermidis ATCC35984 (decrease of 2 to 3 logs) (FIG. 10B) after 24 h of incubation. These observations show that the compositions according to the invention containing denarase prevent the formation of biofilm, and consequently potentiate the effect of an antibiotic on its capacity to reduce the viability within the biofilm. It is understood that the present invention is in no way limited to the embodiments described above and that many modifications can be made thereto without departing from the scope of the appended claims.

For example, denarase was used in the examples, it goes without saying that the examples could have illustrated the activity of benzonase endonuclease® available from the company Millipore Sigma

4.1 Biofilms including Candida

The inventors then attempted to treat biofilms comprising Candida albicans, either in monoculture or in complex biofilm models comprising Candida albicans and prokaryotes. Different strains of Candida albicans have been used; that ATCC24433, as well as strains isolated from orthopedic prosthesis infections. Subtilisin (protease from Bacillus licheniformis) and lyticase (from Arthrobacter luteus or Bacillus subtilis) were obtained from Sigma. The other enzymes are those used above.

The antifungal Caspofungin (Merck Sharp & Dohme) and, for complex biofilms additionally comprising one or more prokaryotes, the antibiotics Moxifloxacin HCl (Bayer) or Meropenem (Mylan) were used (24 hours of treatment, after application of the enzymes).

Cytotoxicity tests were carried out on MG63 osteoblasts and on other types of cells.

Both subtilisin (already at concentrations of about 0.5 U/mL) and Lyticase (already at 10 U/mL) are toxic to osteoblasts, but not necessarily toxic to other cells. These are the concentrations that will be used at the biofilm level.

Surprisingly, the inventors observed that subtilisin (two durations of treatment were tested: 30 minutes and 1 hour) sensitized biofilms comprising Candida albicans (associations with Gram-positive bacteria were tested, here, S. aureus and /or Gram negative; here. E. coli), or consisting solely of Candida albicans. A combination of Denarase® with Lyticase (combination applied 30 minutes or 1 h) also showed a synergistic effect on these biofilms. The combination of subtilisin with Denarase® did not show any advantage over the effect obtained by subtilisin alone at the level of biofilms comprising Candida albicans. The inventors tested a sequential application of a composition comprising Denarase, then subtilisin, with increased efficacy.

Claims

42 CLAIMS

1. Use of a para-pharmaceutiaue or pharmaceutical composition which can be administered to living beings, in particular to human beings, comprising at least one endoribonuclease enzyme chosen from the group consisting of enzymes belonging to the enzymatic classes EC 3.1 .30 and EC 3.1 .31 and their mixture, to potentiate a microbicidal agent, in particular an antibiotic, an antifungal, or a disinfectant, in the treatment and/or the prevention of bacterial infections involving the formation of biofilm.

2. Use of a para-pharmaceutical or pharmaceutical composition which can be administered to living beings, in particular to humans, according to claim 1, in which the treatment and/or prevention of bacterial infections involving the formation of biofilm is a curative or preventive treatment for dermatological infections or infections developing on burns and superficial or deep wounds.

3. Use of a para-pharmaceutical or pharmaceutical composition which can be administered to living beings, in particular to humans, according to claim 1, in which the treatment and/or prevention of bacterial infections involving the formation of biofilm is a curative and/or preventive treatment of post-implantation infections associated with the infection of tissues around a medical device implanted in the body or a medical device implanted in the body.

4. Use of a para-pharmaceutical or pharmaceutical composition that can be administered to living beings, in particular to humans, in the treatment and / or prevention of bacterial infections involving the formation of biofilm according to claim 1, in a personal hygiene or cosmetic care, such as for example a care for the nails, an oral solution, a mouthwash, a toothpaste, an eye bath, an eye lens cleaning solution, an appliance/prosthesis cleaning solution toothbrushes, anti-acne skin care.

5. Use of a para-pharmaceutical or pharmaceutical composition administrable to living beings, in particular to human beings according to any one of claims 1 to 4, in which said composition further comprises a series of additional enzymes, for example one, two, three, four, five, six, seven, eight enzyme(s). 43

6. Use of a para-pharmaceutical or pharmaceutical composition administrable to living beings, in particular to human beings according to claim 5, in which an enzyme of said series of additional enzymes of said composition is chosen from the group consisting of glycosidases (EC 3.2.1), deoxyribonucleases (EC 3.1.21), oxidoreductases (EC 1.), carboxylic ester hydrolases (EC 3.1.1), proteases and peptidases (EC 3.4.; preferably subtilisin), and mixtures thereof.

7. Use of a para-pharmaceutical or pharmaceutical composition which can be administered to living beings, in particular to humans, according to any one of claims 1 to 6, in which said composition comprises at least one second enzyme chosen from the group of glycosidases (EC 3.2.1), preferably a glucanase such as (31,3 endoglucanase, and/or an endoglucanase of the group EC.3.2.1.39.

8. Use of a para-pharmaceutical or pharmaceutical composition which can be administered to living beings, in particular to humans, according to claim 7, in which said composition comprises at least one third enzyme chosen from the group consisting of glycosidases (EC 3.2.1), deoxyribonucleases (EC 3.1.21), oxidoreductases (EC 1), carboxylic ester hydrolases (EC 3.1.1), peptidases and proteases (EC 3.4), and mixtures thereof, in particular chosen in the group consisting of glycosidases (EC 3.2.1) and peptidases (EC 3.4), the composition preferably comprises at least dispersin B, cellulase and endoglucanase ((31,3).

9. Use of a para-pharmaceutical or pharmaceutical composition administrable to living beings, in particular to humans according to any one of claims 1, 3, 5 to 8, in which the treatment and / or prevention Bacterial Infections Involving Biofilm Formation is a curative or preventive treatment for bacterial infection of tissues surrounding an implanted orthopedic implant or the implanted orthopedic implant.

10. Use of a para-pharmaceutical or pharmaceutical composition which can be administered to living beings, in particular to humans, according to any one of claims 1, 3, 5 to 8, in which the treatment and/or prevention bacterial infection involving biofilm formation is a treatment for or prevention of bacterial infection of tissues surrounding an implanted dental implant or the implanted dental implant. 44

1 1. Use of a para-pharmaceutical or pharmaceutical composition administrable to living beings, in particular to human beings according to any one of claims 1, 3, 5 to 8, in which the treatment and / or the prevention of bacterial infections involving the formation of biofilm is a curative or preventive treatment of a bacterial infection of tissues surrounding a catheter, a cannula, a probe, a prosthesis, an endosseous implant, a zygomatic implant, an orthodontic implant, a dental prosthesis, a retainer plate, a valve, a drain, a stent, a tube for artificial respiration or an implanted screw or a catheter, a cannula, a probe, a prosthesis, an endosseous implant, an implant bone, an orthodontic implant, a dental prosthesis, a retainer plate, a valve, a drain, a stent, an artificial respiration tube or an implanted screw.

12. Use of a para-pharmaceutical or pharmaceutical composition which can be administered to living beings, in particular to human beings according to any one of claims 1, 2, 4 to 8, in which the treatment and/or prevention bacterial infections involving biofilm formation comprises an application of said composition to a wound, an infection, tissues or a medical device, preferably an application of a woven or non-woven support impregnated with said para-pharmaceutical or pharmaceutical composition .

13. Use of a para-pharmaceutical or pharmaceutical composition which can be administered to living beings, in particular to human beings according to any one of claims 1, 2, 5 to 8, in which the treatment and/or prevention bacterial infections involving the formation of a biofilm comprises an application of said composition to a wound, an infection, tissues, preferably an application of a dressing in the form of a gel comprising said para-pharmaceutical or pharmaceutical composition.

14. Use of a para-pharmaceutical or pharmaceutical composition which can be administered to living beings, in particular to humans, according to any one of claims 1 to 11, in which the treatment and/or prevention of bacterial infections involving biofilm formation comprises an application of said composition to a wound, infection, tissues or a medical device, preferably an application of an aqueous, preferably buffered solution of said para-pharmaceutical or pharmaceutical composition, by infiltration, by irrigation, by injection, by percutaneous application, by inhalation, by mouthwash or eyewash, by dabbing.

15. Use of a para-pharmaceutical or pharmaceutical composition which can be administered to living beings, in particular to humans, according to any one of claims 1, 2, 4 to 8, in which the treatment and/or the prevention of bacterial infections involving biofilm formation comprises application of said composition to a wound, infection, tissue or medical device, preferably application of a paste, cream, ointment, or a viscous solution comprising said parapharmaceutical or pharmaceutical composition, such as, for example, a toothpaste.

16. Use of a para-pharmaceutical or pharmaceutical composition which can be administered to living beings, in particular to human beings according to any one of the preceding claims, in which said microbicidal agent, in particular said antibiotic and/or antifungal, phage, or said disinfectant and said composition form a combination product for simultaneous, separate or phased use.

17. Para-pharmaceutical or pharmaceutical composition that can be administered to living beings, in particular to humans, comprising at least one endoribonuclease enzyme chosen from classes EC 3.1.30 and EC 3.1.31, preferably at a content of 10 to 1000U/ml, preferably 50 to 500U/ml, preferably from 100 to 500U/ml, such as for example at a content of 200 U/ml to 650 U/ml, more particularly from 250 U/ml to 550 U/ml , preferably from 300 U/ml, or even from 350 U/ml to 500 U/ml.

18. Para-pharmaceutical or pharmaceutical composition which can be administered to humans according to claim 17, in which said at least one endoribonuclease enzyme is of bacterial origin and/or belongs to class EC 3.1.30.1 or EC 3.1.30.2.

19. Para-pharmaceutical or pharmaceutical composition administrable to living beings, in particular to human beings according to claim 17 or claim 18, further comprising a series of additional enzymes, for example one, two, three , four, five, six, seven, eight enzyme(s) .

20. Para-pharmaceutical or pharmaceutical composition administrable to living beings, in particular to human beings according to claim 1, in which an enzyme of said series of additional enzymes of said composition is chosen from the group consisting of glycosidases ( EC 3.2.1), deoxyribonucleases (EC 3.1.21), oxidoreductases (EC 1), carboxylic ester hydrolases (EC3.1.1) and peptidases (EC 3.4), and mixtures thereof, preferably the additional enzyme is glucanase such as 0 1.3 endoglucanase, and/or an endoglucanase from group EC.3.2.1.39.

21. Para-pharmaceutical or pharmaceutical composition administrable to living beings, in particular to human beings according to any one of claims 17 to 20, further comprising at least one second enzyme chosen from the group of glycosidases ( EC 3.2.1).

22. Para-pharmaceutical or pharmaceutical composition administrable to living beings, in particular to human beings according to claim 21, further comprising at least one third enzyme chosen from the group comprising glycosidases (EC 3.2.1), deoxyribonucleases (EC 3.1.21), oxidoreductases (EC 1), carboxylic ester hydrolases (EC 3.1.1), proteases and peptidases (EC 3.4).

23. Para-pharmaceutical or pharmaceutical composition which can be administered to living beings, in particular to human beings according to claim 22, comprising at least one fourth enzyme chosen from the group comprising glycosidases EC 3.2.1), deoxyribonucleases (EC 3.1.21), oxidoreductases (EC 1 ), carboxylic ester hydrolases (EC 3.1.1 ), proteases and peptidases (EC 3.4), preferably comprising as additional enzymes a glucanase such as 0 1 ,3 endoglucanase and/or an endoglucanase of group EC.3.2.1.39, Dispersine B and cellulase.

24. Para-pharmaceutical or pharmaceutical composition which can be administered to living beings, in particular to human beings according to claim 23, comprising at least one fifth enzyme chosen from the group comprising glycosidases (EC 3.2.1), deoxyribonucleases ( EC 3.1.21), oxidoreductases (EC 1), carboxylic ester hydrolases (EC 3.1.1), proteases and peptidases (EC 3.4), preferably subtilisin.

25. Para-pharmaceutical or pharmaceutical composition which can be administered to living beings, in particular to human beings according to claim 24, comprising at least one sixth enzyme chosen from the group comprising glycosidases (EC 3.2.1), deoxyribonucleases ( EC 3.1.21 ), oxidoreductases (EC 1 ), carboxylic ester hydrolases (EC 3.1.1 ), proteases and peptidases (EC 3.4).

26. Para-pharmaceutical or pharmaceutical composition administrable to living beings, in particular to human beings according to claim 25, comprising at least one seventh enzyme chosen from the group comprising 47 glycosidases (EC 3.2.1), deoxyribonucleases (EC 3.1.21), oxidoreductases (EC 1), carboxylic ester hydrolases (EC 3.1.1), proteases and peptidases (EC 3.4).

27. Para-pharmaceutical or pharmaceutical composition administrable to living beings, in particular to human beings according to claim 26, comprising at least one eighth enzyme chosen from the group comprising glycosidases (class EC 3.2.1), deoxyribonucleases (class EC 3.1.21), oxidoreductases (class EC 1.), carboxylic ester hydrolases (class EC 3.1.1), proteases and peptidases (class EC 3.4.), and mixtures thereof.

28. Para-pharmaceutical or pharmaceutical composition administrable to living beings, in particular to humans according to any one of claims 17 to TJ, further comprising at least one microbicidal molecule such as an antibiotic, an antiseptic, antifungal, a phage, or one or more microbicidal peptides (such as an antibiotic and an antifungal) packaged separately or with said endoribonuclease.

29. Para-pharmaceutical or pharmaceutical composition administrable to living beings, in particular to human beings according to any one of claims 17 to 28, further comprising a quorum sensing inhibitor

30. Para-pharmaceutical or pharmaceutical composition administrable to living beings, in particular to human beings according to any one of claims 17 to 29, in the form of a solution, further comprising an enzymatic buffer chosen from the group consisting of Tris-HCl, TGN, TBS, PBS, HEPES, MES, PIPES, MOPS, BES, TES, phosphate buffer and citrate buffer, containing 0 to 2 mM MgCl2, containing 0 to 2 mM CaCl2, and 0 to 500 mM NaCl.

31. Parapharmaceutical or pharmaceutical composition administrable to living beings, in particular to human beings according to any one of claims 17 to 29, in the form of a solution, further comprising an enzymatic buffer comprising 0 to 50% stabilizer (polyol, arginine, calcium formate, glucose).

32. Para-pharmaceutical or pharmaceutical composition administrable to living beings, in particular to human beings according to any one of claims 17 to 31, further comprising at least one surfactant.

33. Para-pharmaceutical or pharmaceutical composition administrable to living beings, in particular to human beings according to any one of claims 17 to 32, further comprising at least one preservative. 48

34. Poro-pharmaceutical or pharmaceutical composition which can be administered to living beings, in particular to human beings according to any one of claims 17 to 33, further comprising at least one sequestrant.

35. Pharmaceutical composition administrable to living beings, in particular to human beings according to any one of claims 17 to 34, in the form of a solution, for example a mouthwash, an eye bath, a lotion, a solution irrigation, a solution for injection.

36. Para-pharmaceutical or pharmaceutical composition according to any one of claims 17 to 34, in the form of a hydrophilic dressing, for example a hydrogel.

37. Para-pharmaceutical or pharmaceutical composition according to any one of claims 17 to 34, in immobilized form on a woven or nonwoven, dry support or on a medical device or in impregnated form on a woven or nonwoven support.

38. Para-pharmaceutical or pharmaceutical composition according to any one of claims 17 to 34, in the form of a topical composition.

39. Para-pharmaceutical or pharmaceutical composition according to any one of claims 17 to 34, in the form of a sterile solution which can be administered by infiltration, by irrigation, by injection, by percutaneous application and by inhalation.

40. Para-pharmaceutical or pharmaceutical composition according to any one of claims 17 to 37 for use as a potentiator of a microbicidal agent, in particular an antibiotic and/or an antifungal, a phage, or a disinfectant, in the treatment and/or prevention of bacterial infections involving biofilm formation.

41. Para-pharmaceutical or pharmaceutical composition according to any one of claims 17 to 38 for use in a curative or preventive treatment of dermatological infections or infections developing on burns and superficial or deep wounds.

42. Para-pharmaceutical or pharmaceutical composition according to any one of claims 17 to 38, for use in curative and / or preventive treatment of post-implantation infections associated with the infection of tissues around a medical device implanted in the body or a medical device implanted in the body. 49

43. Poro-pharmaceutical or pharmaceutical composition according to any one of claims 17 to 38, for use in a body or cosmetic hygiene care, such as for example a care for the nails, an oral solution, a mouthwash, toothpaste, eye bath, eye lens cleaning solution, dental appliance cleaning solution, toothbrush cleaning solution, anti-acne skin care.

44. Para-pharmaceutical or pharmaceutical composition according to any one of claims 17 to 38, for use in a curative or preventive treatment of a bacterial infection of tissues surrounding an implanted orthopedic implant or the implanted orthopedic implant.

45. Para-pharmaceutical or pharmaceutical composition according to any one of claims 17 to 38, for use in a curative or preventive treatment of a bacterial infection of tissues surrounding an implanted dental implant or the implanted dental implant.

46. Para-pharmaceutical or pharmaceutical composition according to any one of claims 17 to 38, for use in a curative or preventive treatment of a bacterial infection of tissues surrounding a catheter, a cannula, a probe, a prosthesis, an implant endosseous, a zygomatic implant, an orthodontic implant, a dental prosthesis, a retainer plate, a valve, a drain, a stent, a tube for artificial respiration or an implanted screw or else a catheter, a cannula, a probe, prosthesis, endosseous implant, zygomatic implant, orthodontic implant, dental prosthesis, retainer plate, valve, drain, stent, artificial respiration tube or implanted screw.

47. Para-pharmaceutical or pharmaceutical composition according to any one of claims 17 to 38 and 41, 42, for use in the treatment and / or prevention of bacterial infections involving the formation of biofilm which comprises an application of said composition on a wound, an infection, tissues or a medical device, preferably an application of a woven or non-woven support impregnated with said para-pharmaceutical or pharmaceutical composition or on which said para-pharmaceutical or pharmaceutical composition is immobilized, for example dried up.

48. Para-pharmaceutical or pharmaceutical composition according to any one of claims 17 to 38 and 41, for use in the treatment and / or prevention of bacterial infections involving the formation of 50 biofilm which comprises an application of said composition to a wound, an infection, tissues, preferably an application of a dressing in the form of a gel, more particularly a hydrogel comprising said parapharmaceutical or pharmaceutical composition.

49. Para-pharmaceutical or pharmaceutical composition according to any one of claims 17 to 38 and 41 to 46, for use in the treatment and / or prevention of bacterial infections involving the formation of biofilm which comprises an application of said composition on a wound, an infection, tissues or a medical device, preferably an application of an aqueous solution, preferably buffered, of said parapharmaceutical or pharmaceutical composition, by infiltration, by irrigation, by injection, by percutaneous application, by inhalation, by mouthwash or eyewash, by dabbing, by soaking.

50. Para-pharmaceutical or pharmaceutical composition according to any one of claims 17 to 38 and 41, for use in the treatment and / or prevention of bacterial infections involving the formation of biofilm which comprises an application of said composition on a wound, infection, tissues or a medical device, preferably an application of a paste or a viscous solution comprising said parapharmaceutical or pharmaceutical composition, such as for example a toothpaste.

51. Para-pharmaceutical or pharmaceutical composition according to any one of claims 28 to 50, for use as a combination product for simultaneous, separate or staggered use over time.

52. Para-pharmaceutical or pharmaceutical composition according to any one of claims 17 to 38 and 41 to 45, for surgical use.

53. Non-therapeutic use of subtilisin (EC.3.4.21.62) for the potentiation of a biofilm comprising Candida albicans to one or more anti-microbiological molecules.

54. Use according to claim 53, in which the anti-microbiological molecules are an antifungal and/or an antibiotic, preferably said antibiotic is an antibiotic effective against Gram-negative bacteria (in planktonic form) and Gram-positive bacteria (in planktonic form). 51

55. Pharmaceutical composition comprising subtilisin (EC.3.4.21.62) for the treatment of a biofilm comprising Candida albicans, said biofilm affecting a patient.

56. Pharmaceutical composition according to claim 55 for sequential use with an antifungal and/or an antibiotic, preferably in which the antifungal is active against Candida albicans (in planktonic form) and the antibiotic is active against bacteria (in planktonic) Gram negative and/or Gram positive.

57. Pharmaceutical composition according to claim 55 or 56 for the curative treatment of tissues surrounding an orthopedic implant, a catheter, a cannula, a probe, a prosthesis, an endosseous implant, a zygomatic implant, an orthodontic implant, a dental prosthesis , a compression plate, a valve, a drain, a stent, a tube for artificial respiration or an implanted screw, of an epidermis, of a wound or of an internal bodily mucosa being infected by a biofilm comprising Candida albicans.